Going from the exciting molecular discovery to the approval of an actual medicinal product is an extremely lengthy and complicated process. Preclinical research acts as the scientific bridge between discovery and human clinical trials. Usually, the duration of preclinical research lasts about 1-3 years and revolves around evaluating candidate molecules in terms of efficacy, metabolic stability, and safety limits.
Biopharmaceutical companies need to gather sufficient proof to test the molecule in humans. Collaboration with a specialized preclinical UK CRO will give companies access to state-of-the-art ADME, pharmacokinetics, and bioanalysis platforms that reduce early technical risks.
The Main Objectives of the Preclinical Evaluation Process
From thousands of lead molecules discovered during the early screening stage, only very few can be considered for human clinical trials. The purpose of preclinical evaluation is to filter promising candidates and remove unviable ones before moving on to costly human trials.
Among the objectives of preclinical research are:
- Determination of Dosing Limits: Establishing maximum doses and exposure limits for subsequent clinical trials.
- Determination of Pharmacokinetic Profiles: Assessing absorption, distribution, metabolism, and excretion of the lead molecule.
- Validation of Target Efficacy: Confirming the biological activity of the lead molecule in appropriate models.
- Establishment of Target Organ Toxicity: Detection of any possible adverse effects on vital organs at the early stage of development.
Key Pillars: ADME, Pharmacokinetics, and Safety Toxicology
The interaction of a drug molecule with biological systems necessitates the performance of a comprehensive pharmacokinetics analysis. Traditionally, poor ADME (Absorption, Distribution, Metabolism, and Excretion) has been one of the primary causes of drug development failure.
Four principal pillars form the basis of modern-day preclinical research:
- Absorption: Analysis of the efficiency of the compound’s entry into systemic circulation.
- Distribution: Analysis of the drug’s ability to reach its target tissue, for instance, crossing the blood-brain barrier in case of central nervous system targets.
- Metabolism: Assessment of the processing of the drug by enzymes found in the liver and intestines in order to avoid drug interactions.
- Excretion: Analysis of the excretion routes and kinetics of the drug from the body.
Combining these studies with safety toxicology analysis will give researchers a comprehensive picture of a lead candidate’s viability.
Translational Disease Models: Validating Efficacy Before First-in-Human Trials
While in vitro testing provides important information on how the compound acts, it is certainly not sufficient to understand how the body will react to this process of treatment. Translational disease models help with this task, replicating the human disease process in a laboratory.
Therapeutic model development depends on the field it is needed for:
- Oncology: Tumor regression, dosing regimen, and activity of biomarkers.
- Neuroscience: Target tissue concentrations in the central nervous system, microdialysis technique.
- Respiratory & Inflammation: Therapeutic activity in airway and lung inflammation models.
With an experienced preclinical UK CRO working together, researchers have all the necessary disease models that give reliable translational data.
Regulatory Compliance: Meeting GLP Standards for IND Submissions
Before beginning Phase 1 trials and securing regulatory approvals from organizations such as MHRA, FDA, and EMA, biopharma companies should file their Investigational New Drug applications. These applications are reviewed by regulatory authorities, which need to verify that preclinical safety data justify human testing.
The following criteria must be complied with for regulatory submissions:
- Good Laboratory Practice Compliance: Ensuring that all relevant toxicology and safety studies have a robust quality management system in place.
- Bioanalytical Assays: The use of highly advanced analytical methods to determine drug and metabolite levels.
- Extensive Safety Profiles: Documenting data on cardiovascular, pulmonary, and central nervous system safety pharmacology.
With these criteria met, regulatory submissions will definitely meet regulatory requirements globally and protect participants of the trial.
De-Risking Therapeutic Pipelines for Clinical Success
Preclinical studies provide the science behind the modern drug discovery process. Conducting comprehensive studies in terms of ADME, toxicology, and translational efficacy will ensure that the research team will be able to make the right decisions regarding compound selection and avoid costly failures during the clinical stage.
Comprehensive preclinical assessment helps turn laboratory results into therapeutic programs for clinical success.
